34811 Treatment of underlying monoclonal gammopathy of clinical significance (MGCS) with lenalidomide for IVIG-resistant scleromyxedema
Belzer A, Bosenberg M, Leventhal J. 34811 Treatment of underlying monoclonal gammopathy of clinical significance (MGCS) with lenalidomide for IVIG-resistant scleromyxedema. Journal Of The American Academy Of Dermatology 2022, 87: ab122. DOI: 10.1016/j.jaad.2022.06.521.Peer-Reviewed Case Reports and Technical Notes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply